These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 9234925

  • 1. Randomized study comparing carboplatin/cyclophosphamide and cisplatin/cyclophosphamide as first-line treatment in patients with stage III/IV epithelial ovarian cancer and small volume disease. German Ovarian Cancer Study Group (GOCA).
    Meerpohl HG, Sauerbrei W, Kühnle H, Schumacher M, Pfleiderer A.
    Gynecol Oncol; 1997 Jul; 66(1):75-84. PubMed ID: 9234925
    [Abstract] [Full Text] [Related]

  • 2. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.
    Swenerton K, Jeffrey J, Stuart G, Roy M, Krepart G, Carmichael J, Drouin P, Stanimir R, O'Connell G, MacLean G.
    J Clin Oncol; 1992 May; 10(5):718-26. PubMed ID: 1569444
    [Abstract] [Full Text] [Related]

  • 3. Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients. 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatin.
    Dittrich Ch, Sevelda P, Salzer H, Obermair A, Speiser P, Breitenecker G, Schemper M, Kaider A, Austrian Ovarian Cancer Study Group.
    Eur J Cancer; 2003 May; 39(8):1129-40. PubMed ID: 12736113
    [Abstract] [Full Text] [Related]

  • 4. Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. A Southwest Oncology Group study.
    Alberts DS, Dahlberg S, Green SJ, Garcia D, Hannigan EV, O'Toole R, Stock-Novack D, Surwit EA, Malviya VK, Jolles CJ.
    Cancer; 1993 Jan 15; 71(2 Suppl):618-27. PubMed ID: 8420685
    [Abstract] [Full Text] [Related]

  • 5. Results of a Southwest Oncology Group phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer.
    Hannigan EV, Green S, Alberts DS, O'Toole R, Surwit E.
    Oncology; 1993 Nov 15; 50 Suppl 2():2-9. PubMed ID: 8233297
    [Abstract] [Full Text] [Related]

  • 6. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
    Meng LH, Kong BH, Zhang YZ, Yang XS, Wang LJ, Su SL, Jiang J, Cui BX, Wang B.
    Zhonghua Fu Chan Ke Za Zhi; 2007 Oct 15; 42(10):683-7. PubMed ID: 18241544
    [Abstract] [Full Text] [Related]

  • 7. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer.
    Alberts DS, Green S, Hannigan EV, O'Toole R, Stock-Novack D, Anderson P, Surwit EA, Malvlya VK, Nahhas WA, Jolles CJ.
    J Clin Oncol; 1992 May 15; 10(5):706-17. PubMed ID: 1569443
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
    du Bois A, Lück HJ, Meier W, Möbus V, Costa S, Richter B, Bauknecht T, Warm M, Schroeder W, Olbricht S, Nitz U, Jackisch C.
    Semin Oncol; 1997 Aug 15; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296
    [Abstract] [Full Text] [Related]

  • 14. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
    Holloway RW, Mehta RS, Finkler NJ, Li KT, McLaren CE, Parker RJ, Fruehauf JP.
    Gynecol Oncol; 2002 Oct 15; 87(1):8-16. PubMed ID: 12468336
    [Abstract] [Full Text] [Related]

  • 15. Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma: an Eastern Cooperative Oncology Group pilot study.
    Grem J, O'Dwyer P, Elson P, Simon N, Trump D, Frontiera M, Falkson G, Vogl S.
    J Clin Oncol; 1991 Oct 15; 9(10):1793-800. PubMed ID: 1919629
    [Abstract] [Full Text] [Related]

  • 16. Second-line chemotherapy with cisplatin-ifosfamide in patients with ovarian cancer previously treated with carboplatin-cyclophosphamide.
    Polyzos A, Tsavaris N, Kosmas C, Petrikos G, Giannikos L, Kalahanis N, Papadopoulos O, Christodoulou K, Giannakopoulos K, Veslemes M, Katsilambros N.
    J Chemother; 1999 Apr 15; 11(2):144-9. PubMed ID: 10326746
    [Abstract] [Full Text] [Related]

  • 17. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.
    Hoskins P, Vergote I, Cervantes A, Tu D, Stuart G, Zola P, Poveda A, Provencher D, Katsaros D, Ojeda B, Ghatage P, Grimshaw R, Casado A, Elit L, Mendiola C, Sugimoto A, D'Hondt V, Oza A, Germa JR, Roy M, Brotto L, Chen D, Eisenhauer EA.
    J Natl Cancer Inst; 2010 Oct 20; 102(20):1547-56. PubMed ID: 20937992
    [Abstract] [Full Text] [Related]

  • 18. Weekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide given for 5 months after cytoreductive surgery for advanced ovarian cancer.
    Bolis G, Favalli G, Danese S, Zanaboni F, Mangili G, Scarabelli C, Tateo S, Valsecchi MG, Scarfone G, Richiardi G, Frigerio L, Melpignano M, Villa A, Parazzini F.
    J Clin Oncol; 1997 May 20; 15(5):1938-44. PubMed ID: 9164205
    [Abstract] [Full Text] [Related]

  • 19. Cisplatin-paclitaxel-cyclophosphamide with G-CSF in primary advanced epithelial ovarian cancer.
    Fanning J, Colgrove M, Phibbs G.
    Gynecol Oncol; 2000 Oct 20; 79(1):97-100. PubMed ID: 11006039
    [Abstract] [Full Text] [Related]

  • 20. A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer.
    Polyzos A, Tsavaris N, Kosmas C, Giannikos L, Katsikas M, Kalahanis N, Karatzas G, Christodoulou K, Giannakopoulos K, Stamatiadis D, Katsilambros N.
    Oncology; 1999 Oct 20; 56(4):291-6. PubMed ID: 10343192
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.